PMID- 37396155
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230704
IS  - 2225-4110 (Print)
IS  - 2225-4110 (Electronic)
IS  - 2225-4110 (Linking)
VI  - 13
IP  - 4
DP  - 2023 Jul
TI  - Hydroalcoholic extract of Passiflora incarnata improves the autistic-like 
      behavior and neuronal damage in a valproic acid-induced rat model of autism.
PG  - 315-324
LID - 10.1016/j.jtcme.2023.02.005 [doi]
AB  - Experimental autism in rodents can be caused by prenatal valproic acid (VPA) 
      exposure. Some diseases, such as attention-deficit hyperactivity disorder (ADHD), 
      insomnia, opiate withdrawal, and generalized anxiety disorder can be treated by 
      consuming Passiflora incarnata, due to the possession of bioactive compounds like 
      alkaloids, phenols, and flavonoids. The present study aims to investigate the 
      role of the hydroalcoholic extract of Passiflora incarnata in behavioral and 
      oxidative stress aberrations induced by VPA. On the gestational day (GD), 12.5, 
      pregnant Wistar rats received VPA (600 mg/kg subcutaneously). Male pups were 
      treated with the extract (30,100, and 300 mg/kg) from postnatal day 35 to the end 
      of the experiment, and underwent behavioral testing to evaluate locomotion, 
      repetitive, and stereotyped movements, anxiety, and social and cognitive 
      behaviors. After behavioral testing, the blood sample was taken from the left 
      ventricle to determine serum catalase (CAT), superoxide dismutase (SOD), 
      malondialdehyde (MDA), and total antioxidant capacity (TAC). Then the animals 
      were euthanized and their brains were taken out for histological assays of the 
      prefrontal cortex (PFC) and CA1 hippocampus with hematoxylin/eosin. The total 
      phenol and flavonoid content and antioxidant activity of the extract were also 
      measured. A significant improvement was observed in behavioral disturbances, 
      particularly with 300 mg/kg of Passiflora. Moreover, the formation of oxidative 
      stress markers significantly decreased at this dose. The extract also reduced the 
      percentage of damaged cells in the CA1 and PFC. The results indicated that 
      Passiflora extract could ameliorate VPA-induced behavioral aberrations possibly 
      due to the antioxidant actions of its bioactive compounds.
CI  - (c) 2023 Center for Food and Biomolecules, National Taiwan University. Production 
      and hosting by Elsevier Taiwan LLC.
FAU - Amini, Fatemeh
AU  - Amini F
AD  - Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.
AD  - Department of Physiology and Pharmacology, Kerman University of Medical Science, 
      Kerman, Iran.
FAU - Amini-Khoei, Hossein
AU  - Amini-Khoei H
AD  - Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord 
      University of Medical Sciences, Shahrekord, Iran.
FAU - Haratizadeh, Sara
AU  - Haratizadeh S
AD  - Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.
FAU - Setayesh, Mohammad
AU  - Setayesh M
AD  - Department of Traditional Medicine, School of Persian Medicine, Kerman University 
      of Medical Sciences, Kerman, Iran.
FAU - Basiri, Mohsen
AU  - Basiri M
AD  - Neuroscience Research Center, Institute of Neuropharmacology, Kerman University 
      of Medical Sciences, Kerman, Iran.
FAU - Raeiszadeh, Mahboobeh
AU  - Raeiszadeh M
AD  - Herbal and Traditional Medicines Research Center, Kerman University of Medical 
      Sciences, Kerman, Iran.
FAU - Nozari, Masoumeh
AU  - Nozari M
AD  - Neuroscience Research Center, Institute of Neuropharmacology, Kerman University 
      of Medical Sciences, Kerman, Iran.
AD  - Department of Physiology and Pharmacology, Kerman University of Medical Science, 
      Kerman, Iran.
LA  - eng
PT  - Journal Article
DEP - 20230223
PL  - Netherlands
TA  - J Tradit Complement Med
JT  - Journal of traditional and complementary medicine
JID - 101605474
PMC - PMC10310915
OTO - NOTNLM
OT  - Autism
OT  - Behavior
OT  - Extract
OT  - Oxidative stress
OT  - Passiflora
OT  - Valproic acid
COIS- The authors declare that there is no conflict of interest associated with this 
      publication and there has been no significant financial support for this work 
      that could have influenced its outcome.
EDAT- 2023/07/03 13:06
MHDA- 2023/07/03 13:07
PMCR- 2023/02/23
CRDT- 2023/07/03 11:16
PHST- 2022/05/27 00:00 [received]
PHST- 2023/01/26 00:00 [revised]
PHST- 2023/02/20 00:00 [accepted]
PHST- 2023/07/03 13:07 [medline]
PHST- 2023/07/03 13:06 [pubmed]
PHST- 2023/07/03 11:16 [entrez]
PHST- 2023/02/23 00:00 [pmc-release]
AID - S2225-4110(23)00019-6 [pii]
AID - 10.1016/j.jtcme.2023.02.005 [doi]
PST - epublish
SO  - J Tradit Complement Med. 2023 Feb 23;13(4):315-324. doi: 
      10.1016/j.jtcme.2023.02.005. eCollection 2023 Jul.